Eli Lilly and Company $LLY Shares Purchased by Formidable Asset Management LLC

Formidable Asset Management LLC grew its position in Eli Lilly and Company (NYSE:LLY) by 9.2% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 12,029 shares of the company’s stock after purchasing an additional 1,013 shares during the period. Eli Lilly and Company comprises approximately 1.9% of Formidable Asset Management LLC’s holdings, making the stock its 9th biggest holding. Formidable Asset Management LLC’s holdings in Eli Lilly and Company were worth $12,927,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in the company. Worth Financial Advisory Group LLC grew its holdings in shares of Eli Lilly and Company by 2.0% in the 4th quarter. Worth Financial Advisory Group LLC now owns 1,369 shares of the company’s stock worth $1,471,000 after purchasing an additional 27 shares during the last quarter. Dorato Capital Management bought a new position in Eli Lilly and Company during the 4th quarter valued at about $36,000. Abacus Planning Group Inc. lifted its holdings in Eli Lilly and Company by 4.7% during the 4th quarter. Abacus Planning Group Inc. now owns 2,595 shares of the company’s stock valued at $2,789,000 after purchasing an additional 116 shares during the last quarter. Catalina Capital Group LLC boosted its position in Eli Lilly and Company by 1.6% in the fourth quarter. Catalina Capital Group LLC now owns 1,197 shares of the company’s stock valued at $1,286,000 after buying an additional 19 shares in the last quarter. Finally, HF Advisory Group LLC boosted its position in Eli Lilly and Company by 440.9% in the fourth quarter. HF Advisory Group LLC now owns 12,025 shares of the company’s stock valued at $12,923,000 after buying an additional 9,802 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently weighed in on LLY shares. Barclays began coverage on shares of Eli Lilly and Company in a report on Thursday, February 19th. They set an “overweight” rating and a $1,350.00 price objective for the company. UBS Group reissued a “buy” rating on shares of Eli Lilly and Company in a report on Wednesday, March 18th. Wall Street Zen upgraded Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research report on Sunday, March 29th. Argus raised their price target on Eli Lilly and Company from $930.00 to $1,200.00 and gave the company a “buy” rating in a report on Monday, February 9th. Finally, Morgan Stanley reiterated an “overweight” rating and issued a $1,313.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, March 5th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and an average price target of $1,222.22.

Eli Lilly and Company Trading Up 0.0%

LLY opened at $935.85 on Friday. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,133.95. The stock has a market capitalization of $884.21 billion, a PE ratio of 40.78, a PEG ratio of 1.09 and a beta of 0.51. The company has a current ratio of 1.58, a quick ratio of 1.19 and a debt-to-equity ratio of 1.54. The firm has a 50-day moving average price of $993.66 and a two-hundred day moving average price of $969.38.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $7.48 by $0.06. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The company had revenue of $19.29 billion for the quarter, compared to analyst estimates of $17.85 billion. During the same period in the prior year, the business earned $5.32 earnings per share. Eli Lilly and Company’s quarterly revenue was up 42.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, equities analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: FDA approves Foundayo (orforglipron), the first once‑daily oral GLP‑1 for chronic weight management with no food/water restrictions — a commercial launch (April 6) and analyst forecasts point to multi‑billion dollar sales potential that is boosting investor sentiment. Eli Lilly (LLY) Receives FDA Approval for Foundayo Weight Management Pill
• Positive Sentiment: Bank of America and other brokers reiterate buy/raise views and price targets after the approval, calling Foundayo a preferred oral GLP‑1 and lifting upside expectations for LLY. Bank of America sees Eli Lilly’s Foundayo as preferred oral GLP-1
• Positive Sentiment: Wall Street models expect a strong commercial debut (analyst revenue scenarios in the billions for 2026), supporting upside to near‑term sales and valuation. Wall Street sees multi-billion dollar debut for Lilly’s obesity pill
• Positive Sentiment: Lilly’s announced acquisition of Centessa (~$7.8B) diversifies the pipeline into neuroscience and is viewed as strategic for long‑term growth beyond metabolic franchises. Eli Lilly to Acquire Centessa Pharmaceuticals
• Neutral Sentiment: Quiet Phase‑1 readout (LY4060874) — no major surprises reported, so limited immediate stock impact but keeps focus on pipeline cadence. LY4060874 Phase 1 Readout
• Neutral Sentiment: Unusually high options activity noted — signals elevated investor/speculator interest around the approval and upcoming launch, but direction uncertain. Eli Lilly Target of Unusually High Options Trading
• Negative Sentiment: Rival Novo Nordisk released cross‑trial comparisons claiming Wegovy’s oral pill produces greater weight loss and fewer adverse events than Foundayo — intensifies competitive risk and could pressure uptake/pricing. Novo Nordisk Wegovy Data Challenges Foundayo
• Negative Sentiment: Broader competitive pressures in weight‑loss drugs — including Novo price cuts/generics in markets like India — highlight margin and pricing risk across the GLP‑1 category. Novo Nordisk price cuts in India
• Negative Sentiment: Policy and macro risk: proposed US tariffs on branded drugs and recent geopolitical tensions have weighed on pharma stocks, capping LLY’s upside despite product news. Trump Administration Unveils Up to 100% Tariff on Branded Drugs LLY Stock Slips As Geopolitical Tensions Weigh

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.